Randomized phase II study of maintenance pemetrexed, bevacizumab, and pemetrexed+bevacizumab after induction chemotherapy with carboplatin+pemetrexed in advanced nonsquamous NSCLC

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2012
INTERVENTION: pemetrexed bevacizumab pemetrexed+bevacizumab CONDITION: nonsquamous NSCLC PRIMARY OUTCOME: 1‐year progression‐free survival rate from randomization. INCLUSION CRITERIA: Induction chemotherapy 1.nonsquamous NSCLC 2.stage IIIB or IV 3.Age <75 4.ECOG PS 0‐1 5.normal organ function 6.Written informed consent Maintenance chemotherapy 1.non‐PD after 4 cycles of induction chemotherapy 2.ECOG PS 0‐1 3.normal organ function
Epistemonikos ID: a7fdf952611955e5200e2e0016315cc576deba7c
First added on: Aug 22, 2024